[1] G. C. Farrell and C. Z. Larter, “Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis,” Hepatology, Vol. 43, No. 2, 2006, pp. 99-112. doi:10.1002/hep.20973
[2] J. D. Browning, L. S. Szczepaniak, R. Dobbins, P. Nur- emberg, J. D. Horton, J. C. Cohen, et al., “Prevalence of Hepatic Steatosis in an Urban Population in the United States: Impact of Ethnicity,” Hepatology, Vol. 40, No. 6, 2004, pp. 1387-1395. doi:10.1002/hep.20466
[3] J. A. Welsh, S. Karpen and M. B. Vos, “Increasing Prevalence of Nonalcoholic Fatty Liver Disease among United States Adolescents, 1988-1994 to 2007-2010,” Journal of Pediatrics, Vol. 162, No. 3, 2013, pp. 496-500. doi:10.1016/j.jpeds.2012.08.043
[4] G. Bedogn, L. Miglioli, F. Masutti, C. Tiribelli, G. Marchesini and S. Bellentani, “Prevalence of and Risk Factors for Nonalcoholic Fatty Liver Disease: The Dionysos Nutrition and Liver Study,” Hepatology, Vol. 42, No. 1, 2005, pp. 44-52. doi:10.1002/hep.20734
[5] X. Hu, Y. Huang, Z. Bao, Y. Wang, D. Shi, F. Liu, et al., “Prevalence and Factors Associated with Nonalcoholic Fatty Liver Disease in Shanghai Work-Units,” BMC Gastroenterology, Vol. 12, No. 1, 2012, p. 123. doi:10.1186/1471-230X-12-123
[6] X. Ying, Y. Jiang, Y. Qian, Z. Jiang, Z. Song and C. Zhao, “Association between Insulin Resistance, Metabolic Syndrome and Nonalcoholic Fatty Liver Disease in Chinese Adults,” Iranian Journal of Public Health, Vol. 41, No. 1, 2012, pp. 45-49.
[7] G. Musso, R. Gambino, S. Bo, B. Uberti, G. Biroli, G. Pagano, et al., “Should nonalcoholic Fatty Liver Disease Be Included in the Definition of Metabolic Syndrome? A Cross-Sectional Comparison with Adult Treatment Panel III Criteria in Nonobese Nondiabetic Subjects,” Diabetes Care, Vol. 31, No. 3, 2008, pp. 562-568. doi:10.2337/dc07-1526
[8] M. Hamaguchi, N. Takeda, T. Kojima, A. Ohbora, T. Kato, H. Sarui, et al., “Identification of Individuals with Non-Alcoholic Fatty Liver Disease by the Diagnostic Criteria for the Metabolic Syndrome,” World Journal of Gastroenterology, Vol. 18, No. 13, 2012, pp. 1508-1516. doi:10.3748/wjg.v18.i13.1508
[9] W. Nseir, A. Shalata, A. Marmor and N. Assy, “Mechanisms Linking Nonalcoholic Fatty Liver Disease with Coronary Artery Disease,” Digestive Diseases and Sciences, Vol. 56, No. 12, 2011, pp. 3439-3449. doi:10.1007/s10620-011-1767-y
[10] C. Ruhl and J. Everhart, “Epidemiology of Nonalcoholic Fatty Liver,” Clinical Liver Disease, Vol. 8, No. 3, 2004, pp. 501-519. doi:10.1016/j.cld.2004.04.008
[11] L. Carulli, A. Lonardo, S. Lombardini, G. Marchesini and P. Loria, “Gender, Fatty Liver and GGT,” Hepatology, Vol. 44, No. 1, 2006, pp. 278-279. doi:10.1002/hep.21218
[12] B. Neal, S. MacMahon and N. Chapman, “Effects of ACE Inhibitors, Calcium Antagonists, and Other Blood Pressure-Lowering Drugs,” Lancet, Vol. 356, No. 9246, 2000, pp. 1955-1964. doi:10.1016/S0140-6736(00)03307-9
[13] G. Donati, B. Stagni, F. Piscaglia, N. Venturoli, A. M. Morselli-Labate, L. Rasciti, et al., “Increased Prevalence of Fatty Liver in Arterial Hypertensive Patients with Normal Liver Enzymes: Role of Insulin Resistance,” Gut, 2004, Vol. 53, No. 7, pp. 1020-1023. doi:10.1136/gut.2003.027086
[14] S. Yokohama, M. Yoneda, M. Haneda, S. Okamoto, M. Okada, K. Aso, et al., “Therapeutic Efficacy of an Angiotensin II Receptor Antagonist in Patients with Nonalcoholicsteatohepatitis,” Hepatology, Vol. 40, No. 5, 2004, pp. 1222-1225. doi:10.1002/hep.20420
[15] J. Stamler, O. Vaccaro, J. Neaton and D. Wentworth, “Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial,” Diabetes Care, Vol. 16, No. 2, 1993, pp. 434-444. doi:10.2337/diacare.16.2.434
[16] A. Adlerberth, A. Rosengren and L. Wilhelmsen, “Diabetes and Long-Term Risk of Mortality from Coronary and Other Causes in Middle-Aged Swedish Men. A General Population Study,” Diabetes Care, Vol. 21, No. 4, 1998, pp. 539-545. doi:10.2337/diacare.21.4.539
[17] R. de Marco, F. Locatelli, G. Zoppini, G. Verlato, E. Bonora and M. Muggeo, “Cause-Specific Mortality in Type 2 Diabetes. The Verona Diabetes Study,” Diabetes Care, Vol. 22, No. 5, 1999, pp. 756-761. doi:10.2337/diacare.22.5.756
[18] G. Marchesini, R. Marzocchi, F. Agostini and E. Bugianesim, “Nonalcoholic Fatty Liver Disease and Metabolic Syndrome,” Current Opinion in Lipidology, Vol. 16, No. 4, 2005, pp. 421-427. doi:10.1097/01.mol.0000174153.53683.f2
[19] N. Sarraf-Zadgan, G. Sadri, H. Malek-Afzali, M. Baghaei, N. Mohammadi-Fard, S. Shahrokhi, et al., “Isfahan Healthy Heart Program: A Comprehensive Integrated Community-Based Program for Cardiovascular Disease Prevention and Control,” Acta Cardiologica, Vol. 58, No. 4, 2003, pp. 309-320. doi:10.2143/AC.58.4.2005288
[20] A. Brea, D. Mosquera, E. Martín, A. Arizti, J. L. Cordero and E. Ros, “Nonalcoholic Fatty Liver Disease Is Associated with Carotid Atherosclerosis: A Case-Control Study,” Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 25, No. 5, 2005, pp. 1045-1050. doi:10.1161/01.ATV.0000160613.57985.18
[21] C. H. Tsai, T. C. Li and C. C. Lin, “Metabolic Syndrome as a Risk Factor for Nonalcoholic Fatty Liver Disease,” Southern Medical Journal, Vol. 101, No. 9, 2008, pp. 900-905. doi:10.1097/SMJ.0b013e31817e8af9
[22] G. N. Ioannou, N. S. Weiss, E. J. Boyko, D. Mozaffarian and S. P. Lee, “Elevated Serum Alanine Aminotransferase Activity and Calculated Risk of Coronary Heart Disease in the United States,” Hepatology, Vol. 43, No. 5, 2006, pp. 1145-1151. doi:10.1002/hep.21171
[23] A. Ugur, T. Sedat, B. Serhat, T. Yusuf, K. Tarkan and C. Atiye, “Association between Nonalcoholic Fatty Liver Disease and Coronary Artery Disease,” Coronary Artery Disease, Vol. 18, No. 6, 2007, pp. 433-436. doi:10.1097/MCA.0b013e3282583c0d
[24] L. Pacifico, V. Cantisani, P. Ricci, J. F. Osborn, E. Schiavo, C. Anania, et al., “Nonalcoholic Fatty Liver Disease and Carotid Atherosclerosis in Children,” Pediatric Research, Vol. 63, No. 4, 2008, pp. 423-427. doi:10.1203/PDR.0b013e318165b8e7
[25] I. S. Okosun, K. M. Chandra, A. Boev, J. M. Boltri, S. T. Choi, D. C. Parish, et al., “Abdominal Adiposity in US Adults: Prevalence and Trends, 1960-2000,” Preventive Medicine, Vol. 39, No. 1, 2004, pp. 197-206. doi:10.1016/j.ypmed.2004.01.023
[26] Y. Lin, H. Lo and J. Chen, “Sonographic Fatty Liver, Overweight and Ischemic Heart Disease,” World Journal of Gastroenterology, Vol. 11, No. 31, 2005, pp. 4838-4842.
[27] J. E. Bartlett, J. W. Kotrlik and C. C. Higgins, “Organizational Research: Determining Appropriate Sample Size for Survey Research,” Information Technology, Learning, and Performance Journal, Vol. 19, No. 1, 2001, pp. 43- 50.
[28] S. Y. Choi, D. Kim, H. J. Kim, J. H. Kang, S. J. Chung, M. J. Park, et al., “The Relation between Non-Alcoholic Fatty Liver Disease and the Risk of Coronary Heartdisease in Koreans,” The American Journal of Gastroenterology, Vol. 104, No. 8, 2009, pp. 1953-1960. doi:10.1038/ajg.2009.238
[29] G. Targher, F. Marra and G. Marchesini, “Increased Risk of Cardiovascular Disease in Non-Alcoholic Fatty Liver Disease: Causal Effect or Epiphenomenon?” Diabetologia, Vol. 51, No. 11, 2008, pp. 1947-1953. doi:10.1007/s00125-008-1135-4
[30] A. Gastaldelli, M. Kozakova, K. Hojlund, A. Flyvbjerg, A. Favuzzi, A. Mitrakou, et al., “Fatty Liver Is Associated with Insulin Resistance, Risk of Coronary Heart Disease, and Early Atherosclerosis in a Large European Population,” Hepatology, Vol. 49, No. 5, 2009, pp. 1537-1544. doi:10.1002/hep.22845
[31] C. Matteoni, Z. Younossi, T. Gramlich, N. Boparai, Y. Liu and A. McCullough, “Nonalcoholic Fatty Liver Disease: A Spectrum of Clinical and Pathological Severity,” Gastroenterology, Vol. 116, No. 6, 1999, pp. 1413-1419. doi:10.1016/S0016-5085(99)70506-8
[32] G. Targher, L. Bertolini, R. Padovani, F. Poli, L. Scala, L. Zenari, et al., “Non-Alcoholic Fatty Liver Disease Is Associated with Carotid Artery Wall Thickness in Diet- Controlled Type 2 Diabetic Patients,” Journal of Endocrinological Investigation, Vol. 29, No. 1, 2006, pp. 55-60.
[33] M. Hamaguchi, T. Kojima, N. Takeda, C. Nagata, J. Takeda, H. Sarui, et al., “Nonalcoholic Fatty Liver Disease Is a Novel Predictor of Cardiovascular Disease,” World Journal of Gastroenterology, Vol. 13, No. 10, 2007, pp. 1579-1584.
[34] M. Ahmed and C. Byrne, “Obstructive Sleep Apnea Syndrome and Fatty Liver: Association or Causal Link?” World Journal of Gastroenterology, Vol. 16, No. 34, 2010, pp. 4243-4252. doi:10.3748/wjg.v16.i34.4243
[35] E. Bugianesi, A. McCullough and G. Marchesini, “Insulin Resistance: A Metabolic Pathway to Chronic Liver Disease,” Hepatology, Vol. 42, No. 5, 2005, pp. 987-1000. doi:10.1002/hep.20920
[36] G. Targher, L. Bertolini, R. Padovani, S. Rodella, G. Zop- pini, L. Zenari, et al., “Relations between Carotid Artery Wall Thickness and Liver Histology in Subjects with Nonalcoholic Fatty Liver Disease,” Diabetes Care, Vol. 29, No. 6, 2006, pp. 1325-1330. doi:10.2337/dc06-0135